U.S. drug giant Pfizer is expected to report significant lower second-quarter revenue tomorrow. Pfizer's laboratories haven't turned out any big-selling new medicines in a decade and it came up empty in a month-long pursuit of British drugmaker AstraZeneca this past spring.

Pfizer is currently conducting trials on several promising drugs, including one to treat breast cancer and vaccines against meningitis and staph infections.

[Metro Networks]